We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of severe pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccination and review of literature.
- Authors
Singh, Ajeet; Bharadwaj, Sujana J.; Chirayath, Anju G.; Ganguly, Satyaki
- Abstract
Vaccines are indeed a boon for tackling the present COVID‐19 pandemic. In India, ChAdOx1 nCoV‐19 (Covishield) is the most commonly used vaccine in the government vaccination program for adults more than 18 years of age. It is a recombinant vaccine developed by Oxford‐Astra Zeneca and manufactured in India by Serum Institute of India (SSI). Here, we report a case of severe pemphigus vulgaris following the second dose of ChAdOx1 nCoV‐19 vaccination in an adult male. The patient developed septicemia during the course of hospital stay, and he was managed with systemic steroids, parenteral antibiotics, and intravenous immunoglobulins (IVIg) along with proper wound care. Patient started improving within 1 month of therapy. This case is being reported in view of the rarity of pemphigus vulgaris following ChAdOx1 nCoV‐19 vaccine.
- Subjects
INDIA; PEMPHIGUS vulgaris; PEMPHIGUS; VACCINATION; LITERATURE reviews; INTRAVENOUS immunoglobulins; WOUND care
- Publication
Journal of Cosmetic Dermatology, 2022, Vol 21, Issue 6, p2311
- ISSN
1473-2130
- Publication type
Case Study
- DOI
10.1111/jocd.14945